Johnson & Johnson

INVEGA™ Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL® in Acutely Ill Hospitalized Patients

In a comparison study between schizophrenia treatments INVEGA™ (paliperidone) Extended-Release Tablets and SEROQUEL® (quetiapine), Invega patients saw schizophrenia symptom improvements as early as five days into therapy and continued through the end of the two-week study period. Results were presented today at the 20th Annual U.S. Psychiatric and Mental Health Congress in Orlando, Florida. - October 13, 2007